Advertisement
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
The public is invited to listen to a live webcast of Kendle's presentationat http://www.kendle.com (click on the link provided in the Investor Eventssection) or at http://cc.talkpoint.com/BEAR002/091007a_sc/?entity=kendle. Anarchived version can be accessed following Kendle's presentation and will beavailable through Oct. 11. Slides accompanying the presentation will beavailable by 9 a.m. Eastern Time on Sept. 11 at http://www.kendle.com in theInvestor Relations section.
Advertisement
About Kendle
Kendle International Inc. (Nasdaq: KNDL) is among the world's leadingglobal clinical research organizations and is the fourth-largest provider ofPhase II-IV clinical development services worldwide. We deliver innovative androbust clinical development solutions - from first-in-human studies throughmarket launch and surveillance - to help the world's biopharmaceuticalcompanies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions -North America, Europe, Asia/Pacific, Latin America and Africa - to meetcustomer needs. With the expertise of our more than 3,000 associatesworldwide, Kendle has conducted clinical trials and provided regulatory andpharmacovigilance services in more than 80 countries. The company was namedthe "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S.Investigative Sites.
Additional information and investor kits are available upon request fromKendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from theCompany's Web site at http://www.kendle.com.
SOURCE Kendle International Inc.
